Other Clinical Trial - To Assess the Efficacy, Safety, & Tolerability of

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05027802` - A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.	Phase 3
Completed	`NCT06064656` - A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Recruiting	`NCT02745158` - The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry	N/A

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT05027802 - A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Phase 3

Completed

NCT06064656 - A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Recruiting

NCT02745158 - The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05090891
Study type	Interventional
Source	Incyte Corporation
Contact	Incyte Corporation Call Center (US)
Phone	1.855.463.3463
Email	medinfo@incyte.com
Status	Recruiting
Phase	Phase 2
Start date	May 5, 2022
Completion date	April 28, 2028

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva — Progress

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms